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Abstract
Background: Only a few studies like ours have investigated the effect of long-term stable iodine supply on thyroid
disorders in a historically iodine-deficient population, but not with a long follow-up time of 10 years.
Methods: Data were derived from two independent population-based cohorts of the Study of Health in Pomerania
(SHIP-0 [1997–2001] and SHIP-TREND [2008–2012]) comprising 4308 and 4420 subjects, respectively. Diagnosed
thyroid disorders were assessed. Thyroid gland dimensions were examined by ultrasound. Levels of serum
thyrotropin (TSH) and autoantibodies to thyroperoxidase (anti-TPO Abs) were measured from blood samples.
Results: Median urinary iodine excretion levels decreased from 123.0 μg/l to 112.0 μg/l (p = <0.001) between 2000
and 2010. The prevalence of known thyroid disorders increased from 7.6 % [CI 6.9–8.5] to 18.9 % [CI 17.6–20.1] and
of thyroid medication use from 6.2 to 11.1 %. The prevalence of goiter decreased from 35.1 to 29.4 % (p = <0.001),
while the prevalence of positive anti-TPO Abs decreased from 3.9 to 2.9 % (p = 0.022). Median serum TSH levels
increased from 0.69 mIU/L to 1.19 mIU/L (p = <0.001). Consequently, prevalence of high TSH (mIU/L) increased from
2.6 to 2.9 % (p = 0.452), and low TSH (mIU/L) decreased from 6.6 to 6.4 % (p = 0.737).
Conclusion: The decreased prevalence of iodine-deficient disorders and a stable prevalence of markers of
autoimmune thyroid disorders argue for an improved iodine supply of the adult population in Northeast Germany.
In contrast, the prevalence of diagnosed thyroid disorders and the intake of thyroid medication increased, although
this might be related to inappropriate therapeutic decisions.
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Background
Until the middle of the 1990s, Germany was considered
a region with mild-to-moderate iodine deficiency. The
improved iodine fortification program implemented in
1993 elevated the median urinary iodine excretion levels
to the lower recommended level [1–3] and reduced goi-
ter prevalence in schoolchildren [2].
The monitoring of iodine fortification programs is im-
portant in order to observe the benefits of iodine fortifi-
cation in populations and to recognize unintended
effects early. Ideally iodine deficiency disorder (IDD)
prevention should result in a decrease of IDD without
significant increase in the prevalence of hypothyroidism
and autoimmune thyroid disorders [4, 5]. An increase in
the prevalence of hypothyroidism may already be in-
duced by moderate increase in intake of iodine [5, 6].
Thus, iodine fortification of salt should always be intro-
duced cautiously.
The main consequences of long-term iodine deficiency
in adults are a high prevalence of goiter, thyroid nodules,
and hyperthyroidism. Data from the first cohort of SHIP
(SHIP-0), which started a few years after the introduc-
tion of the efficient IDD prevention program in
Germany, demonstrated a high prevalence of goiter, thy-
roid nodules, and hyperthyroidism in the general adult
population of Northeast Germany [1]. The question
arises as to whether a further decade of IDD prevention
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program is sufficient to observe a decrease in the preva-
lence of IDD in adults.
Indirectly, the improved iodine supply in Northeast
Germany is mirrored by findings from the five-year
follow-up examinations of SHIP, in which the
normalization rate of baseline goiter was higher than its
incident rate [7]. Similar tendencies were observed for
thyroid nodules and hyperthyroidism. Also, the incidence
rate of positive autoantibodies to thyroperoxidase (anti-
TPO Abs) was lower than its normalization rate [7].
With long-term improved iodine supply in Germany
we now aim to investigate the change in prevalence of
IDD over the last decade, based on two independent
cross-sectional studies. Against this background, the
rationale of our study was to investigate the change in
the prevalence of thyroid disorders between SHIP-0
(1997–2001) and SHIP-TREND (2008–2012). Given a
stable iodine supply, we expect a reduction in the preva-
lence of IDD such as goiter and hyperthyroidism and a
nearly stable prevalence of autoimmune thyroid disor-
ders during the past decade. Particularly younger age




The SHIP project consists of two population-based co-
horts conducted in West Pomerania, a region in North-
east Germany. The project details are given elsewhere
[8, 9]. In SHIP-0, individuals aged 20–79 years were se-
lected from population registries by a two-stage cluster
sampling method. The net sample (without migrated or
deceased persons) comprised 6265 eligible subjects, of
which 4308 (response 68.8 %) participated between 1997
and 2001. A separate stratified random sample of 8826
adults aged 20–79 years was drawn for SHIP-TREND, of
which 4420 subjects participated between 2008 and 2012
(response 50.1 %). Random sample selection in age- and
sex-strata was facilitated by centralization of local popu-
lation registries in the Federal State of Mecklenburg/
West Pomerania.
The invitation procedure for both cohort studies in-
cluded three written invitations, phone calls, and one
personal contact. Additionally, in SHIP-TREND, tempor-
ary examination centres were established in larger com-
munities to facilitate access of older participants to the
study in rural areas.
Assessments
Socio-demographic characteristics and history of diag-
nosed thyroid disorders were assessed by computer-
assisted personal interviews. During data collection,
independent auditors regularly reviewed a random sam-
ple of 10 % of all interviews for quality. All participants
were asked to bring their medications taken seven days
prior to the time of examination. Medication data were
obtained online using the IDOM program (online drug-
database leaded medication assessment) and classified
according to the Anatomical-Therapeutic-Chemical
(ATC) classification system. Thyroid medication was de-
fined by the ATC code H03.
For SHIP-0, serum TSH levels were analyzed by an
immunochemiluminescent procedure (LIA-mat, Byk
Sangtec Diagnostica GmbH, Frankfurt, Germany). The
functional sensitivity of the assay was 0.03 mIU/L [10].
Coefficients of variation for TSH were 5.0 % at 0.3 mIU/L,
3.7 % at 16.1 mIU/l and 8.9 % over the whole study period.
In SHIP-TREND, serum TSH levels were also measured
by an immunochemiluminescent procedure (Dimension
Vista, Siemens, Eschborn, Germany). The functional sen-
sitivity of the TSH assay was 0.005 mIU/L. The inter-assay
coefficients of variations were 2.04 % or 2.20 % for TSH.
A method comparison between the two TSH laboratory
methods showed only negligible differences [11]. Serum
TSH levels were considered low and high based on
the reference range established from data for SHIP-0
(0.25 mIU/L–2.12 mIU/L) and SHIP-TREND (0.49
mIU/L–3.29 mIU/L), respectively [10, 11].
Anti-TPO Abs were measured by an enzyme immuno-
assay in SHIP-0 and SHIP-TREND (VARELISA, Elias
Medizintechnik GmbH, Freiburg, Germany). The func-
tional sensitivity of this assay was 1 IU/ml, and the coef-
ficient of variation over the whole study period was
12 %. The anti-TPO Abs status was defined as follows:
normal < 60 IU/ml in men and < 100 IU/ml in women;
increased ≥ 60 IU/ml in men and ≥ 100 IU/ml in women;
positive: > 200 IU/ml in both sexes [1].
Urinary iodine concentrations were measured from
spot urine samples by a photometric procedure (Pho-
tometer ECOM 6122, Eppendorf, Hamburg, Germany)
with Sandell and Kolthoff reaction in SHIP-0 and SHIP-
TREND [12]. During the course of the study the inter-
assay coefficient of variation for iodine was 4.2 %.
Urinary creatinine concentrations were determined with
the Jaffé method (SHIP-0: Hitachi 717, Roche Diagnos-
tics, Germany, SHIP-TREND: Dimension Vista, Siemens
Healthcare Diagnostics, Eschborn, Germany). The iod-
ine/creatinine ratio was calculated by dividing urinary
iodine by urinary creatinine concentrations.
Thyroid ultrasound
Thyroid ultrasonography was performed in SHIP-0 using
an ultrasound VST-Gateway with a 5 MHz linear array
transducer (Diasonics, Santa Clara, USA). In SHIP-
TREND ultrasonography was performed with a portable
device using a 13-MHz linear array transducer (Vivid-I,
General Electrics, Frankfurt, Germany). In both studies
intra- and inter-observer reliabilities were assessed
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before the start of the study and semi-annually dur-
ing the study. For thyroid volume all inter-observer
and inter-device variabilities showed mean differ-
ences (±2 SD) of < 5 % (<25 %) [13]. Thyroid volume
was calculated as length × width × depth × 0.479 (ml) for
each lobe [14]. Goiter was defined as a thyroid volume ex-
ceeding 18 mL in women and 25 mL in men [15]. The
normal thyroid echo pattern was classified as homoge-
neous. A homogeneous echo pattern with reduced echo-
genicity was defined as hypoechogenic. Nodular changes
exceeding 10 mm in diameter were defined as thyroid
nodules.
Statistical analyses
All analyses were standardized by base-weights to
account for different sampling probabilities. In SHIP-
TREND, additionally, inverse probability weights for
study participation were calculated, which were multi-
plied with the base-weights. For this, data from a non-
responder questionnaire was used, in which 40 % of the
non-responders participated. Variables used for the in-
verse probability weights were marital status, smoking
status, general practitioner (GP) visits, general health,
diabetes mellitus, and history of myocardial infarction
and stroke.
Continuous variables were described by the median
and its 95 % confidence interval (CI). Categorical vari-
ables were described by the prevalence and its 95 % CI.
Differences in median levels between SHIP-0 and SHIP-
TREND were tested by median regression models;
prevalence differences between SHIP-0 and SHIP-TREND
were tested by Poisson regression models. A p < 0.05 was
considered as statistically significant. All analyses were
carried out with Stata 13.1 (Stata Corporation, College
Station, TX, USA).
Results
The median age of the participants was 50 years in
SHIP-0 and 53 years in SHIP-TREND. The frequency of
males was 49.1 % in SHIP-0 and 48.5 % in SHIP-
TREND.
There were 36 individuals excluded from analysis in
SHIP-0 because of missing data regarding diagnosed thy-
roid disorders. Similarly, in SHIP-TREND there were 13
individuals with missing information on known thyroid
disorders.
Diagnosed thyroid disorders and medication
There was an increase in the prevalence of diagnosed
thyroid disorders between SHIP-0 and SHIP-TREND
from 7.6 % [CI 6.9–8.5] to 18.9 % [CI 17.6–20.1]. This
increase was similar for both genders (in males from
12.6 % [CI 11.2–14.2] to 30.5 % [CI 28.4–32.6]; in fe-
males from 2.4 % [CI 1.9–3.2] to 6.5 % [CI 5.5–7.7]).
The increase in prevalence of diagnosed thyroid disor-
ders was observed in all age- and sex-specific strata
(Fig. 1).
The prevalence of thyroid medication intake increased
from 6.2 % [CI 5.5–7.0] in SHIP-0 to 11.1 % [CI 10.1–12.2]
in SHIP-TREND. This increase was more pronounced
Fig. 1 Age- and sex-stratified change in prevalence of diagnosed thyroid disorders (DTD) and thyroid medication (TM) between SHIP-0
and SHIP-TREND
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in males (from 2.1 % [CI 1.6–2.8] to 4.1 % [CI 3.3–5.1])
than in females (from 10.2 % [CI 18.9–11.7] to 17.8 %
[CI 16.0–19.7]). In both studies thyroid hormone ther-
apy was the most frequent thyroid medication used.
We observed an increase in thyroid hormone therapy
from 4.4 % [CI 3.8–5.1] to 10.4 % [CI 9.4–11.4]. This
increase was similar in males (from 1.5 % [CI 1.1–2.1]; to
3.8 % [CI 3.1–4.8]) and females (from 7.1 % [CI 6.1–8.4];
to 16.6 % [CI 14.9–18.4 %] and stronger in the elderly
(Fig. 1).
For further analyses of thyroid-related measurements
we excluded all individuals with diagnosed thyroid disor-
ders and thyroid medication, resulting in study popula-
tions of 3850 individuals (2017 women) in SHIP-0 and
3564 individuals (1975 women) in SHIP-TREND.
Urinary iodine and iodine-to-creatinine excretion levels
There was a significant decrease in median urinary iod-
ine excretion levels between SHIP-0 and SHIP-TREND,
which was more pronounced in females than in males
(Table 1). In SHIP-TREND median urinary iodine excre-
tion levels remained almost stable among all age groups
in males, but increased with advancing age in females
(Fig. 2). Prevalence of median urinary iodine excretion
levels <100 μg/L increased from SHIP-0 to SHIP-
TREND (Table 1). This difference was stronger in fe-
males compared to males and particularly present
among youngest and oldest females (Fig. 2). The median
iodine-to-creatinine ratio declined in all sex- and age-
groups between SHIP-0 and SHIP-TREND with stronger
decrease in females than in males (Table 1).
Thyroid volume and nodules
The median thyroid volume remained similar between
SHIP-0 and SHIP-TREND in the whole study population.
In males, however, there was a considerable decrease in
the thyroid volume between SHIP-0 and SHIP-TREND,
while in females; the thyroid volume did not substantially
differ between the two studies (Table 1).
Goiter prevalence decreased significantly between
SHIP-0 and SHIP-TREND. Again, this decrease was
more pronounced in males than in females and was ob-
served in nearly all age and sex groups except for 50–59
years old females (Fig. 3).
The prevalence of thyroid nodules increased between
SHIP-0 and SHIP-TREND (Table 1). This increase was
more pronounced in females than in males. There was
an age-dependent increase in prevalence of thyroid nod-
ules with highest values in 60–69 year old males and
50–59 year old females.
Hypoechogenic thyroid pattern and anti-TPO Abs
The prevalence of hypoechogenic thyroid pattern de-
creased from SHIP-0 to SHIP-TREND. This decrease
was present predominantly in females, while in males
the prevalence remained almost stable. Within the gen-
der and age groups the strongest decrease was observed
in the age decade of 60–69 years in males and 40–69
years in females (Fig. 4).
Similarly, the prevalence of increased anti-TPO Abs
and positive anti-TPO Abs decreased from SHIP-0 to
SHIP-TREND in the whole study population (Table 1).
While in males the prevalence of increased anti-TPO
Abs and positive anti-TPO Abs was stable between the
studies, there was a decrease in the prevalence from
SHIP-0 to SHIP-TREND in females. No clear trend of
positive anti-TPO Abs prevalence was observed over age
groups in both studies and sexes (Fig. 4).
Thyroid function
Median serum TSH levels increased significantly from
SHIP-0 to SHIP-TREND, resulting in a right shift of
the serum TSH level distribution (Additional file 1:
Figure S1). This increase was stronger in females than
in males (Table 1).
The prevalence of high serum TSH levels remained
almost stable between SHIP-0 and SHIP-TREND. This
increase was seen in males only (Table 1). In SHIP-0
there was no age-dependent tendency in prevalence of
increased serum TSH levels, but in SHIP-TREND mainly
younger individuals between 20 and 49 years were af-
fected (Fig. 5). Likewise, the prevalence of low TSH
remained nearly stable between SHIP-0 and SHIP-
TREND, which was also seen in both sexes (Table 1)
(Fig. 5).
Discussion
In the present study we investigated the effects of long-
term IDD prevention by comparing the prevalence of
thyroid disorders between 2000 and 2010 (7 and 17 years
after the initiation of the iodine fortification program, re-
spectively) based on population-based data from the
same study region of Northeast Germany.
We demonstrate a decrease in the prevalence of goiter
in men and an increase in median serum TSH levels. In
contrast, the prevalence of thyroid nodules increased,
but this could most likely be explained by the better
resolution of the thyroid ultrasound device in SHIP-
TREND than in SHIP-0 [16]. Our data, therefore, argue
for a decline of IDD during the last decade, while the
prevalence of thyroid diseases related to iodine repletion
such as hypothyroidism or positive anti-TPO Abs was
stable or even decreased during that time period.
In contrast to the generally expected trend of subclin-
ical thyroid disorders and, of very important note, self-
reported diagnosed thyroid disorders and treatments
with thyroid medication increased. This is clearly against
the aims of an IDD prevention program, but the
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Table 1 Change in thyroid characteristics between SHIP-0 (1997–2001) and SHIP-TREND (2008–2012)
All Males Females
SHIP-0 SHIP-TREND p* SHIP-0 SHIP-TREND p* SHIP-0 SHIP-TREND p*
Iodine, μg/l 123.0 (122.5; 123.5) 112.0 (111.5; 112.5) <0.001 134.0 (133.2; 134.8) 126.0 (125.5; 126.5) <0.001 108.0 (107.2; 108.8) 91.9 (91.4; 92.4) <0.001
Iodine to creatinine ratio, μg/g 130.1 (129.8; 130.4) 113.7 (113.3; 114.0) <0.001 116.2 (115.7; 116.8) 105.8 (105.4; 106.2) <0.001 152.2 (151.4; 153.0) 128.0 (127.2; 128.8) <0.001
Iodine < 100 μg/L, % 37.7 (36.0; 39.5) 43.9 (42.0; 45.7) <0.001 30.5 (28.2; 32.9) 36.2 (33.9; 38.6) 0.001 45.6 (43.0; 48.3) 53.8 (51.0; 56.6) <0.001
Thyroid volume, ml 18.41 (18.36; 18.46) 18.27 (18.24; 18.30) <0.001 21.79 (21.71; 21.87) 20.39 (20.35; 20.44) <0.001 15.31 (15.26; 15.36) 15.43 (15.40; 15.47) <0.001
Goiter, % 35.1 (33.5; 36.7) 29.4 (27.8; 31.0) <0.001 36.5 (34.2; 38.8) 26.6 (24.7; 28.7) <0.001 33.7 (31.5; 36.0) 32.9 (30.4; 35.6) 0.676
Thyroid nodules, % 18.5 (17.3; 19.8) 30.5 (29.0; 32.1) <0.001 14.8 (13.2; 16.7) 24.4 (22.5; 26.4) <0.001 22.5 (20.7; 24.3) 38.4 (35.9; 41.0) <0.001
Hypoechogenic thyroid pattern, % 5.4 (4.8; 6.2) 3.7 (3.1; 4.4) 0.001 1.8 (1.3; 2.4) 2.6 (1.9; 3.4) 0.113 9.5 (8.1; 11.0) 5.2 (4.1; 6.5) <0.001
Increased anti-TPO antibodies, % 6.7 (5.8; 7.6) 5.2 (4.5; 6.0) 0.013 3.7 (2.9; 4.8) 3.7 (2.9; 4.7) 0.994 9.9 (8.5; 11.5) 7.1 (5.9; 8.6) 0.007
Positive anti-TPO antibodies, % 3.9 (3.2; 4.6) 2.9 (2.4; 3.5) 0.022 1.3 (0.9; 1.9) 1.4 (1.0; 2.1) 0.677 6.7 (5.6; 8.1) 4.7 (3.7; 6.0) 0.017
TSH, mIU/L 0.69 (0.68; 0.70) 1.19 (1.18; 1.20) <0.001 0.68 (0.67; 0.69) 1.16 (1.15; 1.17) <0.001 0.71 (0.70; 0.72) 1.24 (1.23; 1.25) <0.001
Increased TSH, % 2.6 (2.1; 3.2) 2.9 (2.4; 3.6) 0.452 1.6 (1.1; 2.4) 2.4 (1.7; 3.3) 0.122 3.7 (2.9; 4.8) 3.6 (2.7; 4.8) 0.960
Decreased TSH, % 6.6 (5.8; 7.5) 6.4 (5.6; 7.3) 0.737 6.7 (5.6; 8.1) 6.4 (5.4; 7.6) 0.684 6.5 (5.4; 7.7) 6.4 (5.2; 7.8) 0.940
Dichotomous data are presented as percentage and 95 % confidence interval; continuous data as median and 95 % confidence; all analyses are weighted by sampling weights; *p-values for differences between the













question is whether this finding can be related to the im-
proved iodine status of the Northeast German popula-
tion. We assume that a few alternative factors may
explain this phenomenon.
First, an inadequate prescription of thyroxine due to
therapeutic misjudgment may not be ruled out. Data from
the Framingham study demonstrated a high prescription
rate of thyroxine in elderly individuals for non-thyroid in-
dications [17]. In Europe there are also examples for mis-
use of thyroxine. Findings of the DanThyr study from
Denmark showed that levothyroxine might have been pre-
scribed to the wrongly diagnosed thyroid diseases such as
Fig. 2 Age- and sex-stratified change in urinary iodine excretion (UIE) levels between SHIP-0 and SHIP-TREND
Fig. 3 Age- and sex-stratified change in thyroid volume and goiter prevalence between SHIP-0 and SHIP-TREND
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hypothyroidism and hyperthyroidism and their subclinical
forms [18]. Second, the diagnosis of thyroid disorders
depends on the definition of TSH reference intervals. For
example, diagnosis of subclinical hypothyroidism critically
depends on the upper TSH reference limit [19]. As dem-
onstrated in our study there is a substantial increase in
median serum TSH levels between SHIP-0 and SHIP-
TREND. In consequence, the formerly low upper refer-
ence limit established with data from SHIP-0 [10], still
applied in clinical practice, does not adequately represent
the current situation and might have led to an increased
rate of thyroxine prescription. Therefore, we recently
established a new reference interval based on data from
SHIP-TREND, which clearly indicates that the upper
reference limit has to be raised substantially in our study
region [11]. Third, inappropriate treatments may be re-
sponsible for the increase in prevalence of diagnosed thy-
roid disorders and thyroid medication use. Therapeutic
decisions may commonly be based on TSH reference
values only, which according to recent guidelines is con-
sidered a common error [20], as it neglects the symptoms
and complaints of the patient [21]. Finally, increased
awareness about thyroid disorders in recent years, leading
to the frequent use of thyroid laboratory tests, may have
contributed to the higher prevalence of diagnosed thyroid
disorders and consequently, use of thyroid medications.
Additionally, the increased prescription of thyroxine for
the thyroid nodules in SHIP-TREND may not be consider-
able, and further the data are not comparable for the dif-
ferent devices used in the two cohorts. However, owing to
the increased prevalence of thyroid nodules in SHIP-
TREND, this assumption may not be ruled out entirely.
Iodine intake in a population is the major determinant
of thyroid disorders. Even a small change in the level of
iodine intake in a population can change the frequency
of thyroid-related disorders [22]. The median iodine ex-
cretion levels throughout Germany in recent years are
reportedly declining [23]. The German health interview
and examination survey for adults (DEGS 2008–2011)
revealed a drastic decrease (61 μg/L) in iodine excretion
levels, comparing the results (117 μg/L) to the previously
conducted German health interview and examination
Fig. 4 Age- and sex-stratified change in prevalence of hypoechogenic thyroid pattern (HTP) and positive anti-TPO antibodies (anti-TPO Abs)
between SHIP-0 and SHIP-TREND
Fig. 5 Age-stratified frequency distribution of low and high TSH
between SHIP-0 and SHIP-TREND
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survey for children and adolescents (KiGGS 2003–2006)
[3]. Though in comparison to DEGS, in our study the
median iodine excretion levels decreased slightly be-
tween SHIP-0 and SHIP-TREND, but importantly with-
out detrimental effects. Median iodine excretion levels
were lower in females (particularly in younger women)
than in males in both studies. This difference may be ex-
plained by the higher intake of fluids by women compared
to men [24]. A greater than normal intake of water will in-
crease the urine volume, leading to lower urinary creatin-
ine and lower iodine concentrations, but usually will not
reduce the amount of creatinine excreted daily [25]. Thus,
the iodine/creatinine ratio adjusts for differences in fluid
intake and may provide a better estimate of the true iodine
intake in young females [24, 26]. This argument was sup-
ported by the DEGS conclusions [23]. On the other hand,
there was a marginal but significant increase in median
thyroid volume in women, while goiter prevalence
remained nearly unchanged. In contrast, thyroid volume
and goiter prevalence decreased in men. This sex-specific
difference may be explained by a suboptimal iodine status
in women compared to men.
When improving iodine supply there is always a risk
to overcompensate, which might result in a high preva-
lence of autoimmune thyroid disorders. A sudden and
strong increase in iodine intake may provoke the forma-
tion of thyroid antibodies [4, 5, 27]. In our study, there
is no indication of a substantial increase in autoimmune
thyroid disorders parallel to the iodine fortification pro-
gram, which is in line with the longitudinal findings of
the SHIP cohort [7]. We observed a decrease in the
prevalence of elevated and positive anti-TPO Abs be-
tween SHIP-0 and SHIP-TREND. Previous trend studies
have focused on the influence of sudden or periodic in-
crease in iodine supply among the population and of
thyroid autoimmunity [28, 29]. In contrast, we studied
the effect of consistently optimal iodine supply long-
term on the same outcome. In a Chinese study con-
ducted four years after initiation of iodine fortification,
[5] no difference in the five-year incidence rates of thy-
roid autoimmunity was detected. In contrast, a Danish
registry study, studying all new cases of thyroid auto-
immunity, four to five years after mandatory iodine forti-
fication, demonstrated an increase in incidence (32.0 %)
compared to baseline (20.0 %). However, this increase
was in response to increase of iodine intake from previ-
ous moderate and mild to mandatory iodine intake in an
overall cohort [28]. Similarly, a marked increase in inci-
dence of elevated anti-TPO Abs was observed in a study
from Slovenia 10 years after the increase in iodine forti-
fication, leading to an improvement of the iodine supply
from mildly deficient to sufficient [29].
In our study, prevalence of increased and positive anti-
TPO Abs was higher in females than in males, which is
in concordance with other studies [5, 30]. In the Danish
study, [28] prevalence of positive anti-TPO Abs showed
an age-dependent increase with time, which was not ob-
served in our study, as it was highest in middle-aged
(30–60 years) women. However, the age-dependent
prevalence of autoimmune thyroid disorders is strongly
related to the iodine repletion history or sudden increase
in iodine intake in a region [31]. Hence, the decrease in
prevalence of elevated and positive anti-TPO Abs argues
for an optimal but slightly declining iodine supply in our
study region over the past two decades.
It is evident that the current and historical iodine sup-
ply to a region determines the distribution of TSH
values in the population [1]. If the region is iodine-
deficient the TSH reference interval tends to be lower
than in regions with higher iodine supply [10, 32–35].
However, when a region is moving toward sufficiency
from deficiency, initially the TSH distribution may shift
toward the left, as was demonstrated in the SHIP-0
population [10]. With the persistence of improved iodine
supply for several years, the TSH value distribution for
the general population shifts toward the right [11]. Even
the TSH reference range established during the transi-
tion phase from deficiency to sufficiency may not reflect
the current situation [11]. In our study this shift cannot
be explained by different populations, sex, and current
smoking, as these distribution were quite similar be-
tween SHIP-0 and SHIP-TREND [11]. The association
between serum TSH levels and BMI has been previously
reported [36, 37] and although in SHIP-TREND the me-
dian BMI was slightly higher than in SHIP-0, the de-
tected differences in BMI might be too small to explain
this magnitudinal change in TSH values [11]. We as-
sume that the change in TSH is mainly related to the
improved iodine supply. A similar association has been
previously reported for the Danish population [4]. In
contrast to the studies from the US, we could not ob-
serve an increase in TSH levels with age [38, 39]. It may
be explained by the history of iodine deficiency in our
region and more than 60 years of sufficiency in the US
population [40].
Iodine repletion in populations may result in a higher
prevalence of hypothyroidism [41]. A Chinese study, also
conducted in a historically iodine-deficient region after
iodine fortification, showed, in agreement with our
study, no increase in incidence of overt hypothyroidism.
However, there was a slight increase in subclinical
hypothyroidism in that study [5]. In contrast, based on
hospital registry data, a Danish study demonstrated an
increase in incidence of hypothyroidism from 38/
100,000.yr to 48.7/100,000.yr after the increase of iodine
intake from moderate to mild [6]. Differences in results
between our study and the Danish study can be mainly
explained by two factors. First, in the Chinese study and
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in SHIP, the iodine level was almost consistent through-
out the study period [5, 42], while in the Danish study a
periodic increase in iodine intake was introduced [6].
Second, in our study and in the Chinese study the TSH
reference range was adapted to the changing iodine sta-
tus of the study population, which was not done in the
Danish study [5, 43]. Furthermore, the Chinese study
concluded that a shorter follow-up time may be respon-
sible for non-recording of overt hypothyroidism because
of its long latency period. In contrast to the Danish and
the Chinese studies, which had follow-up periods of
eight and five years, our follow-up was conducted
10 years after baseline [5]. Thus, the different follow-up
periods are no explanation for the different findings
across these studies. In our study there is equilibrium in
prevalence of hypo- and hyperthyroidism defined by in-
creased and decreased serum TSH levels in SHIP-
TREND using regional reference limits, which might re-
flect adequate iodine supply over the last 19 years in our
study region.
Strengths of our study are the population-based design
of both studies, which were conducted in the same study
region one decade apart. In both SHIP studies, examina-
tions were executed in the same laboratory with a com-
mon approach to high standardization of measurements.
A limitation is that in SHIP-0 and SHIP-TREND, differ-
ent thyroid ultrasound devices were used, which particu-
larly led to a higher detection rate of thyroid nodules in
SHIP-TREND. Another limitation of our study is that
we have not measured thyroglobulin (Tg) antibodies in
the SHIP studies, which hampers the interpretation of
our findings, since an increase in iodine supply may lead
to an increase in thyroglobulin (Tg) antibody concentra-
tions [44]. However, the slight reduction in prevalence of
positive anti-TPO Abs may indicate that the prevalence
of autoimmune thyroid disorders is stable in our study
region. A further limitation is that we have no data on
fT3 and fT4 in SHIP-TREND, making it impossible to
distinct overt and subclinical forms of thyroid dysfunc-
tion. Additionally, results may be affected by selection
bias as the participation rate decreased to 50.1 % in
SHIP-TREND as compared to 68.8 % in the baseline co-
hort, though inverse probability weights were calculated
for SHIP-TREND study participation and used multipli-
catively to the base-weights to reduce selection bias.
Conclusion
In conclusion, the improved iodine supply over the past
two decades in Germany is paralleled by a reduction in
prevalence of IDDs. Furthermore, there was no increase
in prevalence of markers of autoimmune thyroid disor-
ders, arguing for an optimal iodine supply among the
general adult population in Northeast Germany; how-
ever, the slight decrease in urinary iodine concentrations
may be alarming. In contrast to this, the prevalence of
diagnosed thyroid disorders and the intake of thyroid
medication increased in that time period, which might
be related to inappropriate therapeutic decisions and
more frequent use of thyroid laboratory test in recent
years. Thus, we recommend that therapeutic decisions
should be made with caution, based on regional TSH
reference ranges, the test’s prognostic value, and compli-
ance with treatment.
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